AgeX Therapeutics, Inc. (AGE) |
|
0.567875 0.018 (3.18%)
|
06-06 14:22 |
|
Open: |
0.5504 |
Pre. Close: |
0.5504 |
|
High:
|
0.567875 |
Low:
|
0.53 |
|
Volume:
|
10,980 |
Market Cap:
|
22(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:46:45 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.73 One year: 0.85 |
| Support: |
Support1: 0.47 Support2: 0.37 |
| Resistance: |
Resistance1: 0.62 Resistance2: 0.73 |
| Pivot: |
0.51 |
| Moving Average: |
MA(5): 0.53 MA(20): 0.53 
MA(100): 0.62 MA(250): 0.62 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 86.1 %D(3): 76.1 |
| RSI: |
RSI(14): 54.8 |
| 52-week: |
High: 0.83 Low: 0.37 |
| Average Vol(K): |
3-Month: 21 (K) 10-Days: 25 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AGE ] has closed below upper band by 13.0%. Bollinger Bands are 4.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.55 - 0.55 |
0.55 - 0.56 |
|
Low:
|
0.5 - 0.5 |
0.5 - 0.5 |
|
Close:
|
0.55 - 0.55 |
0.55 - 0.55 |
|
Company Description |
|
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. |
Headline News |
Mon, 05 Jun 2023
Holding back the years: three timeless longevity stocks - Interactive Investor
Tue, 23 May 2023
AgeX Therapeutics Announces Appeal of NYSE American Determination - Yahoo Finance
Thu, 18 May 2023
Is AgeX Therapeutics Inc (AGE) Stock a Smart Investment Thursday? - InvestorsObserver
Wed, 26 Apr 2023
AgeX Therapeutics Receives Stock Exchange Deficiency Letter - Business Wire
Wed, 22 Mar 2023
Juvenescence Now Owns 78.70% of AgeX Therapeutics (AGE) - Nasdaq
Thu, 16 Mar 2023
AGE stock gains after getting $10M loan for restructuring (NYSE:AGE) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
